Harvard Bioscience to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
Harvard Bioscience (Nasdaq: HBIO) will participate in Canaccord Genuity’s MedTech, Diagnostics, and Digital Health and Services Forum on November 11, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Harvard Bioscience (Nasdaq: HBIO) will participate in Canaccord Genuity’s MedTech, Diagnostics, and Digital Health and Services Forum on November 11, 2026. President and Chief Executive Officer John Duke and Chief Financial Officer Mark Frost will hold one-on-one meetings. Duke will also present on the “Emerging Tools for Research and Biopharma Use Cases” panel at 9:30am ET.
Details
News Market Reaction – HBIO
On Nov 4, the day this news came out, HBIO closed 0.69% below the previous close. Our momentum scanner recorded 3 alerts in the available session data.
Data tracked by StockTitan Argus for the Nov 4 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLLISTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Chief Financial Officer, will participate in Canaccord Genuity’s MedTech, Diagnostics, and Digital Health and Services Forum on November 11th, 2026.
Management will participate in one-on-one meetings, and John Duke will present on the “Emerging Tools for Research and Biopharma Use Cases” panel at 9:30am ET.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Company Contact:
Mark Frost
Chief Financial Officer
(508) 893-3120
investors@harvardbioscience.com
